People with schizophrenia die 15‐20 years prematurely. Understanding mortality risk and
aggravating/attenuating factors is essential to reduce this gap. We conducted a systematic …

Objectives: To provide guidance for the management of mood disorders, based on scientific
evidence supplemented by expert clinical consensus and formulate recommendations to …

Importance It has remained unclear whether there are clinically meaningful differences
between antipsychotic treatments with regard to preventing relapse of schizophrenia, owing …

Importance The effectiveness of antipsychotic polypharmacy in schizophrenia relapse
prevention is controversial, and use of multiple agents is generally believed to impair …

People with severe mental illness have a considerably shorter lifespan than the general
population. This excess mortality is mainly due to physical illness. Next to mental illness …

Очередное, четвертое издание монографии, посвященной проблеме депрессий. В
книге, выполненной через 11 лет после выхода в свет в 2003 г. предыдущего издания …

Objective Polypharmacy has been linked to a myriad of adverse consequences, and
escalating rates of polypharmacy present an emerging concern, particularly among older …

Schizophrenia is a debilitating illness with a lifetime prevalence estimate of 0.6% and
consists of symptoms from the positive, negative, and cognitive domains. Social support …

Introduction It has remained controversial if antipsychotic treatment is associated with
increased or decreased mortality among patients with schizophrenia, and if there are any …

BackgroundNumerous treatment guidelines recommend that long-term use of
benzodiazepines (BZD) should be avoided primarily due to development of tolerance and a …